Lupin gains on launch of first product from GAVIS pipeline in the US

The US arm has launched Zolpidem Sublingual Tablets, 1.75mg & 3.5mg used for treatment of insomnia

Shares of Lupin were up over 2% at Rs 1,538 on the Bombay Stock Exchange after the pharma major said that is US-based subsidiary Lupin Pharmaceuticals Inc., has launched the first product from its GAVIS pipeline.

The subsidiary has launched Zolpidem Sublingual Tablets, 1.75mg & 3.5mg which has been approved by the USFDA and final clearance from the FTC with 180 days of exclusivity.

Zolpidem Sublingual Tablets, 1.75mg and 3.5mg are AB-rated generic equivalent of Purdue Pharma L.P's Intermezzo Sublingual Tablets, 1.75mg and 3.5mg and is dispensed for the treatment of insomnia.

The stock opened at Rs 1,506 and touched a high of Rs 1,541. At 11:20am, over 973,000 shares were traded on both the stock exchanges.